PTCT — PTC Therapeutics Cashflow Statement
0.000.00%
- $3.91bn
- $5.15bn
- $806.78m
- 41
- 32
- 99
- 58
Annual cashflow statement for PTC Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -438 | -524 | -559 | -627 | -363 |
Depreciation | |||||
Deferred Taxes | |||||
Non-Cash Items | 158 | 232 | 203 | 252 | 135 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 36.9 | -23.8 | -94.9 | 26.3 | 101 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Payable / Accrued Expenses | |||||
Change in Other Liabilities | |||||
Net Change in Other Assets & Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -194 | -251 | -357 | -158 | -108 |
Capital Expenditures | -17.8 | -28.2 | -32 | -28.4 | -6.5 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -544 | 247 | 322 | -148 | 50.7 |
Acquisition of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -562 | 219 | 290 | -177 | 44.2 |
Financing Cash Flow Items | 611 | 0 | -51.9 | 918 | 224 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 669 | 20.9 | 168 | 646 | 256 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -79.2 | -19.1 | 98.7 | 314 | 185 |